Up to ¥100 Million in Funding Up for Grabs: SATOL Life Science Innovation & Entrepreneurship Competition Now Open for Applications!
Since the dawn of the 21st century, China’s wave of technological innovation has continued to surge forward. Driven by this momentum, emerging technologies—including biotechnology, engineering technology, information technology, and medical technology—have demonstrated immense potential in areas such as precision diagnostics, innovative therapies, and research services, with their adoption and application spreading across an increasing number of industrial segments. In particular, the sudden outbreak of the COVID-19 pandemic in 2020 accelerated the technological revolution within the life sciences industry, propelling the entire sector into a new landscape. Thus, 2021 is poised to become a new starting point for medical innovation in China.
To our colleagues deeply rooted in the life sciences industry, who have also been fortunate to witness its profound transformation: Driven by a confluence of factors—including policy initiatives, technological iterations, market evolution, and the impact of the pandemic—we are seeing the industry embrace the world with unprecedented openness, while emerging technologies such as engineering and medical innovations reshape the future of the life sciences sector.
Amid this ongoing and long-term industrial transformation, local governments, medical innovation enterprises, and tech giants are leveraging their respective strengths to accelerate the precise clinical translation of life sciences technologies and foster the synergistic development of life science research and the medical technology industry.
Amid this major trend, the 2021 SATOL (China) Life Science Technology Innovation and Entrepreneurship Competition has launched its fifth edition and is currently actively recruiting participant projects.
2021-SATOL(China) Life Science Technology Innovation and Entrepreneurship Competition is organized byGuided by the China Association for Science and Technology, the Chinese Academy of Engineering, the Chinese Medical Association, and the Chinese Medical Doctor Association; supported by the Zhejiang Association for Science and Technology, the Zhejiang Venture Capital Association, and the Hangzhou Association for Science and Technology; jointly organized by the Organizing Committee of the World Life Science Conference, SATOL (China) Global Medical Innovation Accelerator Camp, and the 2050 Life Science Club; co-organized by iResearch Consulting, the Management Committee of Hangzhou Liangzhu New City, the Yuhang District Association for Science and Technology, Shulan SATOL Accelerator, and Shengshi ConsultingCo-organized by.
Since its inception in 2017, the SATOL (China) Life Science Technology Innovation and Entrepreneurship Competition has been held for four consecutive editions. More than 60 innovative enterprises have emerged as winners, receiving not only substantial cash prizes and recognition from industry leaders but also valuable opportunities for in-depth exchanges with top-tier resources on a premier platform to explore potential collaborations.
The Chinese market, after several years of development, has become a fertile ground for innovation, even leading the world in certain cutting-edge fields. ThereforeThe Competition Organizing Committee announced the establishment of the “SATOL Global Medical Innovation Center” to promote the clinical translation and practical implementation of life sciences technologies, and to incubate innovative startups in the fields of life sciences and healthcare.
To strengthen direct communication with innovative enterprises,SATOL Global Medical Innovation Center Launches “SATOL Future Medical Technology Leaders Program”, committed to identifying and nurturing outstanding talent and projects with innovation capabilities and growth potential in the life sciences sector, and building an integrated growth and incubation platform for “cultivating future leaders in healthcare and life sciences.”
At the time of this article's publication,SATOL(China) The Life Science Technology Innovation and Entrepreneurship Competition is at a criticalDuring the recruitment period, innovative enterprises continuously inquired about relevant information through various registration channels, while the competition staff were intensively consolidating project application data.Competition Registration Deadline:9Month23Day, if you also wish to leverage industry resources such as cutting-edge technologies and robust capital, while exploring and implementing innovative collaborations with experts across the sector, it is not too late to register now.
The competition focuses on three key tracks: precision diagnostics, innovative therapies, and research services. It emphasizes the interdisciplinary integration and clinical translation of biotechnology, engineering, information technology, and medical technologies, with the aim of identifying leading enterprises in the future healthcare sector.
The pain point identification and solution development for this competition are primarily focused on the following three major scenarios:
Scenario 1: Precision Diagnosis
Scenario Segmentation：Testing platforms, reagent raw materials, clinical mass spectrometry, metabolomics, genetic testing, immunochemistry, molecular diagnostics, microbiome testing, pathological diagnosis, molecular computing, big data and artificial intelligence applications, data interpretation, etc.
Scenario 2: Innovative Therapies
Scenario Segmentation: Cell Therapy, Digital Therapeutics, Robotics and Minimally Invasive Technologies, Artificial Organs, Gene Therapy, Targeted Therapy, Protein Degradation, Foods for Special Medical Purpose (FSMP), Novel Physical Therapies, Biomaterials, Biological Products, Live Biotherapeutic Products, etc.
Scenario 3: Research Services
Scenario Segmentation: Medical Big Data, Drug Discovery, CRO, CDMO, Antibody R&D, R&D Facilities and Equipment, Reagents and Consumables, Model Organisms, Data-Driven Biological Design, etc.
Schedule Settings
1, From now until September 23, 2021, participating entities may register by scanning the QR code below:
2, the competition adopted a parallel model of recruitment and preliminary rounds, with the preliminary rounds conducted through online batch roadshows; the first preliminary round was completed on August 31,Multiple preliminary rounds will also be held in September to select the finalist enterprises.. Interested enterprises are encouraged to register as soon as possible, participate in the preliminary roadshows in advance, and secure their spots in the finals ahead of the competition.
3, the entire duration of this competitionAstraZeneca, Tigermed, Sequoia Capital, China Life Insurance Fund, Hangzhou High-Tech Investment Group, Noah Holdings, Qiming Venture Partners, GIC, Eli LillyLeading pharmaceutical and medical device companies, as well as renowned investment institutions in the healthcare sector, will conduct the review, which will be based onMarket Prospects, Clinical Value, Technological Level, Business Plan, and Team: Five Key DimensionsScore the entries to select the finalists.
4, October 23–24, the competition judges will conduct specialized evaluations of the participating companies to select20 high-quality project companies, from which 10 Innovation Awards and 10 Entrepreneurship Awards were respectively selected.
1, Direct access to the 5th World Life Science and Technology Conference, with face-to-face exchanges with 30+ academicians
2021-SATOLThe (China) Life Science Startup Competition is one of the main events of the 5th World Life Science Conference.The 5th World Life Science and Technology Conference will be held in Hangzhou in November 2021. At that time,The 20 winning enterprises will receive their awards at the opening ceremony of the conference and gain priority access to introductions to renowned global investment firms, clinical research institutions, and large healthcare organizations in the life sciences sector. The competition rankings will also be simultaneously published in top-tier domestic and international industry media as well as financial and business news outlets., facilitate widespread dissemination and enhance corporate influence.
2, nine major implementation incentive policies including project funding of up to RMB 100 million
The competition prioritizes support for innovative entrepreneurial teams in the life sciences sector that have achieved advanced innovations, made breakthroughs in key technologies, and demonstrate strong commercialization potential. The top 20 winning project teams will receive the following implementation incentives:
（1) Project funding of up to RMB 100 million
(2) Support from a concessionary equity investment guidance fund of up to RMB 20 million
(3) Up to RMB 10 million Angel Dream Fund
(4) Up to RMB 10 million in R&D subsidies
(5) New Drug Rewards of Up to RMB 10 Million
(6) Equipment subsidy of up to RMB 5 million
(7) A maximum settlement allowance subsidy of 3 million yuan
(8) Up to RMB 1.2 million in home purchase subsidies
(9) Tax incentives of up to 80% of local retained tax revenue
3. Credit Support from the Competition’s Partner Banks
SATOL (China) Life Sciences Startup Competition aims to build a highly interactive and cohesive community for medical innovation and entrepreneurship, bringing together policymakers, clinical experts, scientists, industry investors, and medical entrepreneurs to jointly seek optimal healthcare solutions under objective conditions. Driven by the explorations of industry participants behind such competitions, an increasing number of innovative enterprises and solutions have emerged, deeply integrating various emerging technologies with disease diagnosis and treatment pathways, and carrying out cutting-edge practices in disease treatment and management from both clinicians’ and industry perspectives.
Seek direction through reflection, and discover truth through practice. In this autumn season fragrant with osmanthus blossoms, we look forward to meeting you at the SATOL (China) Life Science Startup Competition, where we will discuss the future of healthcare and chart the course for the development of the life science industry.